CORPORATE PRESS RELEASE
NORGINE LAUNCHES ZIVEREL® IN AUSTRIA, BELGIUM, LUXEMBOURG AND SWITZERLAND
- ZIVEREL® designed to protect and repair oesophageal mucosa
LONDON. Wednesday 24 May 2017, 07:00 BST. Norgine B.V. today announced that ZIVEREL® is now available in Austria, Belgium, Luxembourg and Switzerland. ZIVEREL® is a Class III medical device for the protective treatment of the oesophageal mucosa. ZIVEREL® is currently the only liquid treatment designed to protect and repair the oesophagus, offering rapid relief from the symptoms of gastro-oesophageal reflux.
Gastro-oesophageal reflux disease is prevalent worldwide, and disease burden may be increasing. It affects up to 20% of the Western population and is associated with a range of risk factors.
Peter Martin, Chief Operating Officer, Norgine said, “We are pleased to make ZIVEREL® available in additional countries including Austria, Belgium, Luxembourg and Switzerland. This will ensure that patients have access to this important treatment. ZIVEREL® protects and repairs the gastro-oesophageal mucosa and offers prolonged relief from the symptoms of this burdensome condition.”
ZIVEREL® is a non-reimbursed medical device that does not require a medical prescription. Prices are applicable per market.
ZIVEREL® is already available from Norgine in Spain. Further launches of ZIVEREL® are anticipated throughout 2017.
Norgine has the commercialisation and distribution rights for ZIVEREL® in Australia, Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland and the UK.
Notes to Editors:
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Isabelle Jouin, T: +44 (0)1895 453643
Charlotte Andrews, T: +44 (0)1895 453607
Follow us @norgine
 ZIVEREL® Instructions for Use, Sept. 2016
 J Dent et al. Gut2005;54:710-717 doi:10.1136/gut.2004.051821. http://gut.bmj.com/content/54/5/710.full